Year-to-date Product Sales growth of 13% (17% at CER1) to $17,315m included third-quarter Product Sales of $6,132m (+16%, +18% at CER). The third quarter again saw all three therapy areas and every sales region
produce encouraging performances, including:
¾ The continued performance of new medicines2, with sales growth in the quarter of 62% (+64% at CER) to
$2,707m, including new-medicine growth in Emerging Markets of 85% (90% at CER) to $539m
¾ Sales growth by therapy area in the quarter: Oncology +46% (+48% at CER) to $2,334m, New CVRM3 +8%
(+11% at CER) to $1,113m and Respiratory +15% (+18% at CER) to $1,319m
¾ Sales growth by region in the quarter: total Emerging Markets sales grew by 25% (29% at CER) to $2,123m,
with China sales growth of 35% (40% at CER) to $1,283m, ahead of longer-term trends. US sales increased
by 17% to $2,025m; Europe sales continued their return to growth, increasing by 1% (4% at CER) to
$1,139m; Japan sales increased by 31% (27% at CER) to $657m
https://www.astrazeneca.com/content/dam ... cement.pdf